findmyKOL
Clinical trialNCT00262730CompletedPhase 2Interventional

Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM

SponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrollment97Glioblastoma Multiforme
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Biological therapies, such as poly ICLC, may stimulate the immune system in different ways and stop tumor cells from growing. Giving poly ICLC after radiation therapy and temozolomide may stop any remaining tumor cells from growing. PURPOSE: This phase II trial is studying how well giving radiation therapy together with temozolomide followed by temozolomide and poly ICLC works in treating patients with newly diagnosed glioblastoma multiforme.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham

    Birmingham, Alabama, United States

  • H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

    Tampa, Florida, United States

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia, United States

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, United States

  • Josephine Ford Cancer Center at Henry Ford Hospital

    Detroit, Michigan, United States

  • Wake Forest University Comprehensive Cancer Center

    Winston-Salem, North Carolina, United States

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio, United States

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jan 2006
Primary completion
31 Aug 2009
Completion
30 Apr 2010
Last update posted
12 Jun 2019
Registered enrollment
97
Registry id
NCT00262730

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.